Abstract
All medically stable infants weighing ≥2,000 grams without contraindications should receive the first dose of hepatitis B vaccine (trade names: Engerix-B®, Recombivax HB®) within 24 hours of birth. Certain infants at increased risk of acquisition of hepatitis B, such as infants born to hepatitis B-infected mothers or mothers with unknown status, should receive hepatitis B vaccine as soon as possible after birth along with a dose of hepatitis B immune globulin. The second dose should be administered a minimum of 4 weeks after the first dose and between 1-2 months of age. The third dose should be administered a minimum of 8 weeks after the second and 16 weeks after the first, between 6-18 months of age. All children not previously vaccinated should receive the age-appropriate dose of hepatitis b vaccine, preferably at 11 or 12 years but up to 18 years of age. The usual schedule for adolescents is two doses separated by no less than 4 weeks, and a third dose at least 8 weeks from the second dose and 16 weeks from the first dose, and preferably 4 to 6 months after the second dose. An approved alternative schedule for adolescents 11 to 15 years of age is two 1.0-mL doses of the Recombivax HB® vaccine separated by 4 to 6 months. Adults at increased risk of hepatitis B infection (including sex partners or household contacts of hepatitis B infected persons; sexually active persons not in a long-term mutually monogamous relationship; persons seeking evaluation or treatment for a sexually transmitted disease; men who have sex with men; current or recent injection drug users; residents and staff of facilities for developmentally disabled persons; health care and public safety workers at risk of exposure to blood or body fluids; persons with end-stage renal disease or diabetes mellitus; HIV-infected individuals; and international travelers to countries with high or intermediate endemnicity) should be vaccinated. If using Recombivax HB® or Engerix-B®, the first two doses should be separated by at least 4 weeks and a third dose administered 4-6 months after the second dose. If using HEPLISAV-B™ vaccine, only two doses (0.5 mL each) are given one month apart, but both doses must be HEPLISAV-B™. Persons with chronic liver disease (including, but not limited to, those with hepatitis C virus [HCV] infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal) should also be vaccinated.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Epidemiology and Prevention of Vaccine-Preventable Diseases, K.A. Hamborsky J, Wolfe S Editor. 2015, Centers for Disease Control and Prevention: Washington D.C.
Schillie, S., C. Vellozzi, and A. Reingold, Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep, 2018. 67(1): p. 1–31.
Mast, E.E., et al., A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep, 2005. 54(Rr-16): p. 1–31.
Mast, E.E., et al., A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep, 2006. 55(Rr-16): p. 1–33; quiz CE1-4.
Schillie, S., et al., Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant. MMWR Morb Mortal Wkly Rep, 2018. 67(15): p. 455–8.
Zuckerman, J.N., Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol, 2006. 78(2): p. 169–77.
Ocama, P., C.K. Opio, and W.M. Lee, Hepatitis B virus infection: current status. Am J Med, 2005. 118(12): p. 1413.
Immunization Action Coalition. Merck discontinues production of Comvax vaccine (Hib-HepB). IAC Express 2014 [cited 2018 March]; Issue 1136:[Available from: http://www.immunize.org/express/issue1136.asp#IACX6.
Leads from the MMWR. Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. JAMA, 1988. 260(2): p. 165, 169–70.
Implementation of newborn hepatitis B vaccination—worldwide, 2006. MMWR Morb Mortal Wkly Rep, 2008. 57(46): p. 1249–52.
Terrault, N.A., et al., AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016. 63(1): p. 261–83.
Terrault, N.A., et al., Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018. 67(4): p. 1560–99.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Dudley, M.Z. et al. (2018). Hepatitis B. In: The Clinician’s Vaccine Safety Resource Guide. Springer, Cham. https://doi.org/10.1007/978-3-319-94694-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-94694-8_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-94693-1
Online ISBN: 978-3-319-94694-8
eBook Packages: MedicineMedicine (R0)